ArticleMolecular and clinical oncology2016

Infusion site adverse events in breast cancer patients receiving highly emetic chemotherapy with prophylactic anti-emetic treatment with aprepitant and fosaprepitant: A retrospective comparison.

Takashi Tsuda et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.